Theriva Biologics (TOVX) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The continuation of the VIRAGE clinical trial, a Phase 2b study for a new pancreatic cancer therapy, has been endorsed by experts after a positive review of its safety and feasibility. This trial tests VCN-01, an innovative treatment combined with standard chemotherapy, and has shown promise with no new toxicities observed, even after a second dose. The trial is proceeding smoothly and is expected to finish enrolling patients by mid-2024.
For further insights into TOVX stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
